German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Since 2020, clinicians can prescribe – and SHI funds will reimburse – medical apps and digital health treatments, the so-called “DiGAs”. The BfArM assesses these DiGAs
Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,
On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with
Despite strong opposition and critique raised by almost all stakeholders, the draft law on the financial stabilization of statutory health insurance (GKV-FinStG),
Following on from the EU regulation for medical devices (MDR) that came into force over one year ago, this week I am